Silent corticotroph adenomas
A Ben-Shlomo, O Cooper - Pituitary, 2018 - Springer
Abstract Purpose Silent corticotroph adenomas (SCAs) present clinically as non-functioning
adenomas (NFAs) but are immunopositive for adrenocorticotrophic hormone (ACTH) without …
adenomas (NFAs) but are immunopositive for adrenocorticotrophic hormone (ACTH) without …
Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review
F Langlois, DST Lim, CG Yedinak, I Cetas… - Pituitary, 2018 - Springer
Abstract Purpose Silent corticotroph adenomas (SCAs) are clinically silent and non-
secreting, but exhibit positive adrenocorticotropic hormone (ACTH) immunostaining. We …
secreting, but exhibit positive adrenocorticotropic hormone (ACTH) immunostaining. We …
Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial
RL Batista, NRC Musolino, VAS Cescato… - American Journal of …, 2019 - journals.lww.com
Background: Complete tumor removal by transsphenoidal surgery is usually difficult for large
nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for …
nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for …
The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis
Introduction Data on silent corticotroph tumor (SCT) are still heterogeneous and
controversial. In this study, we aimed to compare the demographic, clinicopathological …
controversial. In this study, we aimed to compare the demographic, clinicopathological …
A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas
A Jahangiri, JR Wagner, M Pekmezci, A Hiniker… - …, 2013 - journals.lww.com
BACKGROUND: Silent corticotrophic adenomas (SCAs) stain adrenocorticotropic hormone
(ACTH)+ without causing Cushing disease. SCAs are reportedly more aggressive, but …
(ACTH)+ without causing Cushing disease. SCAs are reportedly more aggressive, but …
Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas
OBJECTIVE Nonfunctioning pituitary adenomas are benign, slow-growing tumors. After
gross-total resection (GTR) or subtotal resection (STR), tumors can recur or progress and …
gross-total resection (GTR) or subtotal resection (STR), tumors can recur or progress and …
Recurrence of silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis
Abstract Context The 2017 WHO Classification of Pituitary Tumors grades silent corticotroph
adenomas (SCAs) as “high-risk adenomas” due to their aggressive clinical behavior (high …
adenomas (SCAs) as “high-risk adenomas” due to their aggressive clinical behavior (high …
Silent corticotroph adenomas
O Cooper - Pituitary, 2015 - Springer
Abstract Purpose Silent corticotroph adenomas (SCAs) comprise 20% of all corticotroph
adenomas and 3–19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical …
adenomas and 3–19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical …
Silent (clinically nonfunctioning) pituitary adenomas
SE Mayson, PJ Snyder - Journal of neuro-oncology, 2014 - Springer
Silent, or clinically nonfunctioning, pituitary adenomas can arise from any anterior pituitary
cell type. Some are “clinically silent” in that they result in a supranormal serum concentration …
cell type. Some are “clinically silent” in that they result in a supranormal serum concentration …
Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients
AL Pappy, A Savinkina, C Bicknese, S Neill… - Pituitary, 2019 - Springer
Background Personalized postoperative management of patients with pituitary adenomas
requires an early risk stratification system. Methods We reviewed 501 cases operated …
requires an early risk stratification system. Methods We reviewed 501 cases operated …